P2, N=8, Active, not recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Jul 2026

This study integrated established diagnostic standards, laryngostroboscopy for clinical assessment, and histopathology as the gold standard for grading, while the analysis of SOX2 gene expression showed a promising predictive molecular marker for tumorigenesis.

Paclitaxel (PTX), a broad-spectrum anti-tumor drug, is extensively employed as a first-line chemotherapy for solid tumors, including lung and breast cancers. Compared with PTX-treated mice, S-ketamine administration resulted in significant improvements across behavioral, molecular, and electrophysiological dimensions: significantly increased mechanical withdrawal thresholds indicated alleviated neuropathic pain; Increased central area distance/total distance ratio in the OFT and prolonged open arm time in the EPM demonstrated reduced anxiety-like behaviors; concomitant decreases in mGluR5 expression and pyramidal neuron firing rates were observed alongside enhanced theta-gamma phase-amplitude coupling, and upregulation of BDNF and TrkB expression in the PrL was detected. S-ketamine mitigates PTX-induced mechanical allodynia and anxiety-like behaviors, an effect that is closely associated with the downregulation of mGluR5 and the concurrent modulation of the BDNF/TrkB signaling pathway in the PrL of the mPFC.

By analyzing plasma DNA from individuals harboring germline TP53 mutations, patients receiving radiotherapy, and liver transplantation recipients, we demonstrate that ctDNA shortening can be distinguished from phagocytosis-associated cfDNA shortening through differences in the amplitude and scale parameters of intra- and inter-nucleosomal components. Moreover, leveraging tumor-related fragmentomic alterations, characterized by increased fragmentation entropy identified through cfDNA size deconvolution, significantly enhances cancer detection.

Testing these cell lines for their behavior and sensitivity to different PARP inhibitors, we find that saruparib, a first-in-class PARP1-specific inhibitor, promotes the release of certain PARP1 catalytic mutants and resistance to this inhibitor. We also characterize a PARP1 catalytic mutant with intact mono(ADP-ribosyl)ation activity but devoid of poly(ADP-ribosyl)ation, enabling us to demonstrate a significant contribution of mono(ADP-ribosyl)ation toward PARP1 release from sites of DNA damage.

P1, N=120, Recruiting, AstraZeneca | Active, not recruiting --> Recruiting

P1/2, N=156, Recruiting, Eikon Therapeutics | N=72 --> 156

Within a wide concentration range from 1 pg/mL to 100 ng/mL, the modulation depths of the resonance amplitude exhibit strong linear relationships with concentration, indicating a broad dynamic sensing range...This approach improves spectral resolution and detection reliability, enabling both qualitative identification and quantitative analysis. Overall, the proposed THz sensing platform exhibits ultrasensitive and good reproducibility, providing a promising tool for brain tumor screening and monitoring.

TEG effectively identified hypercoagulability in murine and human breast cancer, normalized by aspirin in mice. This supports TEG's potential for dynamic CAT risk stratification for personalized prophylaxis.

We developed a multi-AM frequency HMIgFUS technique for improved ablation lesion monitoring, and showed slower tumor growth and improved survival in mice treated with multi-AM frequency HMIgFUS.

P1/2, N=72, The First Affiliated Hospital Of Anhui Medical University; Chengdu Zenitar Biomedical Technology Co. Ltd

P3, N=700, Recruiting, AstraZeneca